At a glance
ClinicalIndex Comparison RecordN/ACompleted· 207 enrolled
Drug / intervention
300mg netupitant/0.5mg palonosetron hydrochloridedrug
Likely dose
300mg netupitant/0.5mg palonosetron hydrochloridefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV, Real World Observational Study On The Use Of Akynzeo® (Netupitant/Palonosetron) For The Prevention Of Nausea and Vomiting in Oncology Patients Receiving Highly Emetogenic Chemotherapy (HEC) Over Multiple Cycles.
In Brief
An observational study evaluating 300mg netupitant/0.5mg palonosetron hydrochloride for Chemotherapy-Induced Nausea and Vomiting. Completed, enrolled 207 participants across 17 sites.
Detailed Summary
This Canadian, multi-centre, prospective, observational real-world study is designed to collect patient-reported outcome data on the use of Akynzeo® (netupitant/palonosetron) for the prevention of nausea and vomiting in oncology patients receiving highly emetogenic chemotherapy (HEC).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChemotherapy-Induced Nausea and Vomiting
CountriesCanada
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartOct 2018
Primary CompletionDec 2019
Study CompletionJan 2020
TodayJul 2026
First PostedAug 28, 2018
Enrollment StartOct 3, 2018
Primary CompletionDec 30, 2019
Study CompletionJan 30, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.8 years ago
Interventions
300mg netupitant/0.5mg palonosetron hydrochloridedrug
Antiemetic (NK1 receptor antagonist/5-HT3 receptor antagonist)